Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.

NCT ID: NCT06949579

Last Updated: 2026-02-05

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-28
• Study Completion Date: 2027-12-31

Brief Summary

In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included.

600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset.

Besides the standard of care, blood samples will be collected.

All data collected will be stored in an onlie Castor database

Detailed Description

Main objective: To characterize the phenotype, genetics and biology of myopic staphyloma in a European population (three countries involved).

Primary Outcome Measure:

The primary objective of this study is to identify genetic variants (SNPs) significantly associated with the presence of posterior staphyloma in individuals of European ancestry with high myopia.

A genome-wide association study (GWAS) will be conducted in 600 highly myopic Caucasian participants, divided into two well-phenotyped groups:

• 300 patients with posterior staphyloma (case group)
• 300 patients without posterior staphyloma (control group) SNP allele frequencies will be compared between the two groups using logistic regression models adjusted for relevant covariates (age, sex, axial length, and genetic ancestry via principal components).

The primary endpoint is the identification of SNPs s reaching genome wide significance (p < 5×10-⁸)after correction for multiple testing.

Secondary Outcome Measures:

1. Functional annotation and biological pathway enrichment of associated loci Genome-wide significant SNPs will undergo functional annotation to identify nearby genes, regulatory regions, or non-coding variants with putative biological function.

Pathway and gene ontology enrichment analyses (e.g., KEGG, Reactome, GO) will be performed to highlight potential biological mechanisms contributing to posterior staphyloma pathogenesis.

2. Association with retinal imaging phenotypes Exploratory analyses will assess the relationship between genome wide significant variants and quantitative retinal imaging traits, including: subfoveal choroidal thickness,axial length,staphyloma depth, stpahyloma location, scleral curvature… These associations will be evaluated using multivariable linear regression models, adjusted for potential confounders.

3. Association with structural complications of posterior staphyloma Further exploratory analyses will investigate whether genome wide significant

SNPs are associated with major strutural complications of posterier staphyloma, such as :

macular atrophy,Bruch's membrane ruptures,choroidal neovascularization,foveoschisis, retinal detachment, visual fonction These analyses aim to uncover genetic markers linked to disease severity or progression

4. Differential expression of disease-relevant plasma/ serum protein biomarkers between groups, quantified by mass spectrometry, and correlated with clinical phenotype severity or progression (e.g., visual acuity loss, anatomical changes on OCT)

5. Efficiency and quality of iPSC reprogramming from peripheral blood mononuclear cells (PBMCs) in each study group, 4 individuals (1 male and 1 female myopic patient with staphyloma and 1 male and 1 female myopic patient without staphyloma, aged 30 to 35) assessed by reprogramming success rate, pluripotency marker expression, and genomic integrity. Derived iPSCs will be used differentiate retinal pigment epithelial cells in order to compare disease-relevant cellular phenotypes and functional responses in vitro.

Conditions

High Myopia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

AM A : High Myopia without myopic staphyloma

Group Type: EXPERIMENTAL

blood sampling for DNA

Intervention Type: BIOLOGICAL

Blood sampling for DNA and serum and plasma colection and PBMC

ARM B : High myopia with myopic staphyloma

Group Type: ACTIVE_COMPARATOR

blood sampling for DNA

Intervention Type: BIOLOGICAL

Blood sampling for DNA and serum and plasma colection and PBMC

Interventions

blood sampling for DNA

Blood sampling for DNA and serum and plasma colection and PBMC

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Adults with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with and without posterior staphyloma

• Adults aged 18 years or over
• Patient with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with good quality retinal imaging
• Patient who has signed a consent form to participate in the study
• Patient who is a beneficiary of a social security scheme or who is entitled to it

Exclusion Criteria

• Any systemic or ocular pathologies with an impact on the posterior segment of the eye

• Patient with a systemic pathology likely to affect the posterior segment of the eye:
• Diabetes
• Systemic inflammatory disease: sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, Horton's disease
• Patients with retinitis pigmentosa
• Patients with syndromic myopia
• Patients with myopia associated with a genetic disease such as hereditary vitreoretinopathy
• Patients under guardianship, curatorship or legal protection, as well as pregnant or breastfeeding women (article L1121-5 of the CSP).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

URC-CIC Paris Descartes Necker Cochin

OTHER

Sponsor Role: collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Francine BEHAR-COHEN, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Cochin Hospital

Paris, , France

Countries

France

Central Contacts

Francine Behar-Cohen, MD, PhD

Role: CONTACT

francine.cohen@aphp.fr

06 60 97 44 19 ext. +33

Valérie PLENCE, Msc

Role: CONTACT

valerie.plence-fauroux@aphp.fr

01 58 41 11 78 ext. +33

Other Identifiers

APHP240842

Identifier Type: -

Identifier Source: org_study_id